Examination of Effectiveness, safety, of Cetuximab as 1st-line treatment for KRAS wild type colorectal cancer.

Examination of Effectiveness, safety, of Cetuximab as 1st-line treatment for KRAS wild type colorectal cancer. - Examination of Effectiveness, safety, of Cetuximab as 1st-line treatment for KRAS wild type colorectal cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005488

Enrollment

100

Registered

2011-04-25

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient who has histologically colorectal cancer and KRAS wild type. 2) Patient who was treated by Cetuximab as 1st-line for Kras wild type colorectal cancer.

Exclusion criteria

Exclusion criteria: Patients who are inadequate by investigator's decision.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression-free survival, Overall survival, Safety profile, Conversion rate of nonresectable liver metastases to resectable	—

Countries

Japan

Contacts

Public ContactMasataka Ikeda Tsunekazu Mizushima

Multicenter Clinical Study Group Osaka Colorectal Cancer Treatment Group

tmizushima@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results